Certuity LLC Sells 1,343 Shares of Novo Nordisk A/S (NYSE:NVO)

Certuity LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 25.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,857 shares of the company’s stock after selling 1,343 shares during the quarter. Certuity LLC’s holdings in Novo Nordisk A/S were worth $332,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Beacon Financial Group increased its position in Novo Nordisk A/S by 7.8% during the fourth quarter. Beacon Financial Group now owns 2,707 shares of the company’s stock worth $233,000 after acquiring an additional 195 shares during the period. Warther Private Wealth LLC increased its holdings in shares of Novo Nordisk A/S by 14.2% during the 4th quarter. Warther Private Wealth LLC now owns 12,021 shares of the company’s stock worth $1,034,000 after purchasing an additional 1,497 shares during the period. Leavell Investment Management Inc. raised its position in shares of Novo Nordisk A/S by 13.6% during the fourth quarter. Leavell Investment Management Inc. now owns 3,968 shares of the company’s stock valued at $341,000 after buying an additional 475 shares during the last quarter. Portfolio Design Labs LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $208,000. Finally, Augustine Asset Management Inc. acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $1,693,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 2.3 %

Shares of NYSE:NVO opened at $81.78 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $366.99 billion, a P/E ratio of 24.86, a P/E/G ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The company’s 50-day moving average price is $90.45 and its two-hundred day moving average price is $110.60.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Analyst Ratings Changes

NVO has been the subject of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.